ReviewInvestigative and clinical urology2016
Immune checkpoint blockade therapy for bladder cancer treatment.
Review in Investigative and clinical urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02863913 (A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Muscle-invasive Bladder Cancer), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Muscle-invasive Bladder Cancer
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Elucidating the multifaceted role of MGAT1 in hepatocellular carcinoma: integrative single-cell and spatial transcriptomics reveal novel therapeutic insights.Frontiers in immunology · 2024Article
- The Role of Checkpoint Inhibitor Expression Directly on Exfoliated Cells from Bladder Cancer: A Narrative Review.Diagnostics (Basel, Switzerland) · 2023Review
- Mutational signature and clonal relatedness of recurrent urothelial carcinomas with aristolochic acid.Frontiers in oncology · 2022Article
- Study on Molecular Information Intelligent Diagnosis and Treatment of Bladder Cancer on Pathological Tissue Image.Frontiers in medicine · 2022Article
- Article
- Prognostic value of immune cell infiltration in bladder cancer: A gene expression-based study.Oncology letters · 2020Article
- Bioinformatics Analysis Finds Immune Gene Markers Related to the Prognosis of Bladder Cancer.Frontiers in genetics · 2020Article
- Immune checkpoint inhibitors for urothelial carcinoma.Investigative and clinical urology · 2018Review
- Prognostic roles of tumor associated macrophages in bladder cancer: a system review and meta-analysis.Oncotarget · 2018Article
- Unmasking molecular profiles of bladder cancer.Investigative and clinical urology · 2018Review
- Checkpoint Blockade Rescues the Repressive Effect of Histone Deacetylases Inhibitors on γδ T Cell Function.Frontiers in immunology · 2018Article
- Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.Nanomedicine (London, England) · 2017Review
- From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis.World journal of clinical oncology · 2017Review
- Article
- Changing landscape of diagnosis and treatment of bladder cancer.Investigative and clinical urology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Bladder cancer remains the most immunogenic and expensive malignant tumor in the United States today. As the 4th leading cause of death from cancer in United States, Immunotherapy blocking immune checkpoints have been recently been applied to many aggressive cancers and changed interventions of urological cancers including advanced bladder cancer. The applied inhibition of PD-1-PD-L1 interactions can restore antitumor T-cell activity and enhance the cellular immune attack on antigens. The overall goals of this short review article are to introduce current cancer immunotherapy and immune checkpoint inhibitors, and to provide new insight into the underlying mechanisms that block immune checkpoints in tumor microenvironment. Furthermore, this review will address the preclinical and clinical trials to determine whether bladder cancer patients could benefit from this new cancer therapy in near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.